Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

ARNA 4.56 -0.21 (-4.40%)
price chart
A Realistic View Of Belviq In The Short Term
Over my 10-year career trading biotechs, I have found that retail investors are all too often unrealistic about new therapies and the subsequent appreciation of a company's common stock. The retail crowd surrounding ARNA appears to be repeating this ...
Related articles »  
VIVUS Shares Hit Hard after Earnings
Obesity drug manufacturer VIVUS (NASDAQ: VVUS) slumped 22 percent in early trade Tuesday, as the company reported a net loss of $40.40 million or $0.40 per share in the third quarter.
Vivus Or Arena: Who Has The Edge?  Seeking Alpha
Vivus Weight-Loss Drug Launch In Early Trouble  TheStreet.com
Related articles »  
South Korea's Ildong Pharma To License Arena Pharma Drug
29, 2012) - U.S.-based Arena Pharmaceuticals, Inc. has licensed its internally discovered thrombosis drug, temanogrel, to Seoul, Korea-based Ildong Pharmaceutical Co.
Related articles »  
CEO of the Year, Final Round: Arena Pharmaceuticals vs. Lumber Liquidators
On one hand we have Jack Lief of Arena Pharmaceuticals, who led his company to develop Belviq, the anti-obesity drug recently approved by the FDA that's currently in the driver's seat to be the first fat-busting drug approved internationally (all ...
Arena Pharma Sinks Under Weight Of Vivus' Troubles
Despite having split economics on Belviq, ARNA now trades at a substantial premium to VVUS. The most worrisome disclosure by Vivus Tuesday was the fact that 30% of patients willing to try Qsymia and who get actually get a prescription from their doctor ...
Related articles »  
Vivus, Arena shares jump on insurance coverage for diet pills
N) said it would provide coverage for diet pills of Vivus Inc (VVUS.O) and Arena Pharmaceuticals Inc (ARNA.O), sending the obesity drugmakers' shares up.
Vivus, Arena, Orexigen Get a Bounce After Aetna Says It Will Cover Diet Pills  Minyanville.com
Vivus Jumps on Aetna Qsymia Ruling: San Francisco Mover  Bloomberg
Related articles »  
Ray Dalio's Bridgewater Associates Plunge into ETFs
B) (+238,397 shares), BCE Inc (BCE) (+436,937 shares), Microchip Technology Inc (MCHP) (+422,376 shares) and Nucor Corp (NUE) (+329,712 shares).
Related articles »  
Theravance: Still A Buy On Weakness
More recently, over the last month, negativity in the markets was acute: the S&P is down 2.5%, while the pharmaceutical ETF is down even more, declining 7%. Arena Pharmaceuticals (NASDAQ:ARNA), VVUS Inc. (NASDAQ:VVUS), and Theravance Inc.
FSD Drugs Advance as Women Push for Equal Access
In July, investors raised $20 million for startup Sprout Pharmaceuticals, which hopes to succeed where Boehringer Ingelheim failed by bringing flibanserin through development phases to market.
Google's New Shopping Tool and a Black Friday App
Google has a new, free tool to help you with your holiday gifting. Don't do any online shopping until you've added this to your browser.